Showing results (11-20 of 31) with videos related to
Sort By:
Pageof 4
Cancer|April 19, 2018
Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trialMargaret K Guerriero, Mary W Redman, Kelsey K Baker, et al.Head & Neck|April 11, 2016
Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experienceDaisuke Araki, Mary W Redman, Renato Martins, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.Clinical Lung Cancer|September 23, 2023
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart ReviewJürgen Wolf, Pierre-Jean Souquet, Koichi Goto, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2021
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic AnalysisDavid Planchard, Benjamin Besse, Harry J M Groen, et al.The Oncologist|May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland CancersXiuning Le, Christina Baik, Jessica Bauman, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief ReportXiuning Le, Christina Baik, Byoung Chul Cho, et al.The Lancet. Oncology|March 28, 2024
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trialEgbert F Smit, Enriqueta Felip, Dipesh Uprety, et al.Head & Neck|April 25, 2025
Dual PD-1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland CancersCristina P Rodriguez, Qian Vicky Wu, Kevin Ng, et al.JCI Insight|December 20, 2019
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLCJulia Kargl, Xiaodong Zhu, Huajia Zhang, et al.Pageof 4